The Asia Pacific Biosimilars Market is expected to witness market growth of 25.4% CAGR during the forecast period (2022-2028).
Almost all healthcare system stakeholders may benefit from biosimilars. By providing a less expensive treatment option, they can cut costs while giving patients more options for care. In fact, patients can benefit from the competition sparked by the entry of biosimilars into the market by receiving high-quality biologic products at lower costs. In comparison to the reference products, the introduction of biosimilars presents opportunities for cost savings for payers, employers, state and federal governments, and patients.
Treatments for rare diseases frequently make use of expensive orphan drugs. Although biosimilars for these orphan medications are being developed, they still have many practical obstacles to overcome. For phase I and III trials, it is challenging to gather a sizable, non-heterogeneous population. Additionally, it can be disproportionately expensive to produce enough batches of the biosimilar to conduct batch-to-batch variability studies and compile extensive comparability data.
Due to the region's high population, rising hospital population, increasing cancer prevalence, and growing hospital number, significant growth in the region is anticipated. Due to the presence of numerous emerging players in the region, the Asia-Pacific biosimilar production is expected to rise in the nations like India & China. The region's geriatric population is linked to a high burden on healthcare spending, and this market segment is demanding lower-cost alternatives like biosimilars, which can boost revenue.
The China market dominated the Asia Pacific Biosimilars Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $4,505.4 million by 2028. The Japan market is poised to grow at a CAGR of 24.6% during (2022 - 2028). Additionally, The India market is expected to experience a CAGR of 26.1% during (2022 - 2028).
Based on Application, the market is segmented into Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Granulocyte-Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Insulin and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA
Almost all healthcare system stakeholders may benefit from biosimilars. By providing a less expensive treatment option, they can cut costs while giving patients more options for care. In fact, patients can benefit from the competition sparked by the entry of biosimilars into the market by receiving high-quality biologic products at lower costs. In comparison to the reference products, the introduction of biosimilars presents opportunities for cost savings for payers, employers, state and federal governments, and patients.
Treatments for rare diseases frequently make use of expensive orphan drugs. Although biosimilars for these orphan medications are being developed, they still have many practical obstacles to overcome. For phase I and III trials, it is challenging to gather a sizable, non-heterogeneous population. Additionally, it can be disproportionately expensive to produce enough batches of the biosimilar to conduct batch-to-batch variability studies and compile extensive comparability data.
Due to the region's high population, rising hospital population, increasing cancer prevalence, and growing hospital number, significant growth in the region is anticipated. Due to the presence of numerous emerging players in the region, the Asia-Pacific biosimilar production is expected to rise in the nations like India & China. The region's geriatric population is linked to a high burden on healthcare spending, and this market segment is demanding lower-cost alternatives like biosimilars, which can boost revenue.
The China market dominated the Asia Pacific Biosimilars Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $4,505.4 million by 2028. The Japan market is poised to grow at a CAGR of 24.6% during (2022 - 2028). Additionally, The India market is expected to experience a CAGR of 26.1% during (2022 - 2028).
Based on Application, the market is segmented into Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Granulocyte-Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Insulin and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA
Scope of the Study
Market Segments Covered in the Report:
By Application- Oncology Diseases
- Blood Disorders
- Chronic & Autoimmune Diseases
- Others
- Monoclonal Antibodies
- Granulocyte-Colony Stimulating Factor
- Erythropoietin
- Human Growth Hormone
- Insulin
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Intas Pharmaceutical Ltd
- Novartis AG (Sandoz)
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Fresenius SE & Co. KGaA
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Biosimilars Market by Application
Chapter 5. Asia Pacific Biosimilars Market by Type
Chapter 6. Asia Pacific Biosimilars Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Amgen, Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Intas Pharmaceutical Ltd
- Novartis AG (Sandoz)
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Fresenius SE & Co. KGaA
Methodology
LOADING...
